Research explained · Reviewed September 15, 2026
CJC-1295 and ipamorelin offer two interesting routes into hormone-signalling research. Their distinct targets make them useful subjects for understanding how biological signals become measurable responses.
Start with the formulation
CJC-1295 is discussed as a growth-hormone-releasing hormone analogue. The terms “DAC” and “no-DAC” are important because they should not be treated as minor variations on an otherwise interchangeable product. A 2024 scientific briefing separately reviewed CJC-1295 forms with and without DAC, and documented differences in the available evidence. Read the formulation and evidence assessment.
DAC means drug affinity complex. Its chemical modification permits binding to albumin, a protein in blood. This is part of the rationale for studying a longer-acting molecule, but it does not establish that forms with and without DAC share the same behaviour. Read the pharmacology assessment.
A useful reading habit is to write down the exact name, chemical form and formulation used in a paper before applying its findings to a product listing. If a study concerns a long-acting form, its duration cannot simply be transferred to an item described as no-DAC. Names used in marketing may be less precise than the formulation description in the methods.
What the CJC-1295 human study measured
Two randomized, placebo-controlled, double-blind trials published in 2006 studied a long-acting CJC-1295 formulation in healthy adults. They investigated safety, pharmacokinetics and hormone responses over relatively short study periods. GH and IGF-1 concentrations increased after administration. These findings establish a hormone response under those study conditions; they do not establish long-term improvements in muscle growth, sleep or ageing-related outcomes. Read the original CJC-1295 trials.
GH means growth hormone. IGF-1 is insulin-like growth factor 1, another signal in this biological system. Both can be measured in blood, but a change in a biomarker is not the same thing as a demonstrated benefit that a person can feel or use.
Ipamorelin has a different research history
Ipamorelin acts through the ghrelin receptor. One randomized, placebo-controlled phase 2 trial studied intravenous ipamorelin after bowel surgery, focusing on postoperative gastrointestinal recovery. The study enrolled 117 people and analysed 114. It found no statistically significant differences in the primary or secondary efficacy outcomes. This clinical setting is very different from general wellness or fitness use. Read the postoperative trial.
The result should be interpreted within that setting. It is neither proof of broad wellness benefit nor a complete answer to every possible research question about the molecule.
| Finding or label | What still needs evidence |
|---|---|
| GH or IGF-1 changes | Meaningful clinical outcomes and longer-term safety |
| Two different signalling targets | Benefits and risks of the actual combination |
| A study of one CJC form | Whether another formulation behaves the same way |
The next question: studying the combination
Studying a combination is an opportunity to build on what is known about each component. Separate papers on each ingredient cannot determine the combined response, appropriate exposure, adverse effects or longer-term consequences. A trial would need to test the actual combination with relevant comparison groups and outcomes.
When reviewing a stack claim, look for the exact formulation, the studied population, the route, the duration and the outcomes. “Studied in humans” is only the beginning of that assessment. The reference library lists different CJC and ipamorelin entries; their different labels are a reason to verify identity, not assume that one paper applies to all of them.